Lung Cancer—Non-Small Cell Metastatic

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)  

 
Suresh S. Ramalingam, Tudor Eliade Ciuleanu, Adam Pluzanski, et al.
 
The abstract concludes: 
With 3 y minimum follow-up, NIVO + IPI continued to provide durable and long-term OS benefits vs chemo for pts in 1L aNSCLC. Pts with PD-L1 ≥ 1% who achieved CR/PR at 6 mo had marked OS benefit with NIVO + IPI vs chemo. No new safety signals were identified for NIVO + IPI. Clinical trial information: NCT02477826
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
—————————————————————————————————————————————————————————————————————————————
 
9501 Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
 
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo Dols, et al. 
 
The abstract concludes: 
CheckMate 9LA met its primary endpoint: a statistically significant improvement in OS was observed with NIVO + NSCLC-optimized IPI + a limited course of chemo vs chemo (4 cycles) in 1L advanced NSCLC. No new safety signals were reported. Clinical trial information: NCT03215706.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
—————————————————————————————————————————————————————————————————————————————
 
 
Natasha B. Leighl, Scott Andrew Laurie, Glenwood D. Goss,et al.
 
The abstract concludes: 
The addition of CT to first-line DT did not improve OS in advanced NSCLC. CT+DT improved ORR and PFS, and was associated with greater toxicity. No differential effects were seen by PD-L1 TPS nor bTMB. These data suggest that adding chemotherapy to ICI may be beneficial in those with PD-L1 TPS >=50%, and warrant further analysis in independent datasets. Clinical trial information: NCT03057106.
—————————————————————————————————————————————————————————————————————————————
 
 
Delvys Rodriguez-Abreu, Melissa Lynne Johnson, Maen A. Hussein, et al.
 
The abstract concludes: 
Treatment with TA compared to PA showed clinically meaningful improvement in ORR and PFS in ITT. The safety profile of TA was similar to PA.
—————————————————————————————————————————————————————————————————————————————
 
9504 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
 
Egbert F. Smit, Kazuhiko Nakagawa, Misako Nagasaka, et al.
 
The abstract concludes: 
T-DXd demonstrated promising clinical activity with high ORR and durable responses in pts with HER2-mutated NSCLC. The safety profile was generally consistent with previously reported studies. Clinical trial information: NCT03505710.
—————————————————————————————————————————————————————————————————————————————
 
 
Anas Gazzah, Charles Ricordel, Sophie Cousin, et al.
 
The abstract concludes: 
SAR408701 shows promising antitumor activity in heavily pretreated advanced NSQ NSCLC pts with high CEACAM5 expression. SAR408701 was well tolerated, with minimal hematological toxicity compared to conventional chemotherapy; keratopathy was reversible and manageable with dose modification. These data support the activity of SAR408701 in NSQ NSCLC CEACAM5 high expressors. A phase 3 trial evaluating the activity of CEACAM5-DM4 ADC monotherapy in comparison with docetaxel in NSQ NSCLC CEACAM5 high expressors after failure of standard first line chemotherapy and anti-PD1/PD-L1 is underway. Clinical trial information: NCT02187848.
—————————————————————————————————————————————————————————————————————————————
 
 
Makoto Maemondo, Tatsuro Fukuhara, Haruhiro Saito, et al.
 
The abstract concludes: 
The additional effect of bevacizumab on erlotinib monotherapy for NSCLC with EGFR mutations gradually decreased in the order of PFS2 and survival, with no significant differences. Clinical trial information: UMIN000017069.
—————————————————————————————————————————————————————————————————————————————
 
 
Julia K Rotow, Daniel Botelho Costa, Cloud P. Paweletz, et al.
 
The abstract concludes: 
Combination therapy with osimertinib and gefitinib is tolerable for first-line treatment of EGFR-mutated NSCLC and resulted in rapid plasma clearance of the EGFR mutation. The observed ORR is consistent with previously reported first-line response rates to osimertinib. Analysis of survival outcomes and acquired resistance mechanisms are pending data maturity and will facilitate understanding of the role of first-line dual EGFR TKI therapy for this pt population. Clinical trial information: NCT03122717.
—————————————————————————————————————————————————————————————————————————————
 
 
Xiaoshan Wang, Ming Zeng;
 
The abstract concludes: 
Upfront stereotactic radiotherapy to sites at diagnosis along with first line TKI improved both progression-free survival and overall survival significantly compared with TKI alone. This finding suggests aggressive local therapy to sites at diagnosis should be explored further in large cohort phase III trials as a standard treatment option in this clinical scenario. Clinical trial information: NCT02893332.
—————————————————————————————————————————————————————————————————————————————
 
 
DISCUSSANT
Rachel E. Sanborn, MD | Earle A. Chiles Research Institute, Providence Cancer Institute
 
—————————————————————————————————————————————————————————————————————————————
 
Read the comment by Dr. Julia Judd and Dr. Hossein Borghaei in the ASCO DAILY NEWS:
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
 
Poster Session
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Lung (Abstracts #9501, 9502, 9503)
Access Content Now